News Releases

Year

06 Jun '23

Main Results of Annual and Extraordinary General Meeting

The Annual and Extraordinary General Meeting (the "2023 AGM") of Alvotech (the "Company") was held on June 6, 2023 at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg. Here are the main results of the 2023 AGM. The 2023 AGM approved the Company’s annual

06 Jun '23

Granting of Stock Options

The Annual General Meeting of Alvotech (the “Company”) resolved on June 6, 2023 to grant to certain members of the board a total of 109,524 shares through stock option agreements. The stock options will be granted to four independent board members. The aim of the stock option agreements is to align

31 May '23

Alvotech to Participate in Jefferies Healthcare Conference

REYKJAVIK, Iceland, May 31, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies Healthcare Conference in New York on June 7,

HTML íslensk útgáfa

26 May '23

Transactions of Managers and Closely Associated Persons

Attached is an announcement regarding transactions of managers and closely associated persons. Attachments: Managers Transaction CSSF Form - ATP Holdings ehf 20230524.pdf

24 May '23

Filing of Information Related to Press Release on Agreement Between Alvotech and Advanz Pharma

Information related the press release issued on May 24, 2023 by Alvotech and Advanz Pharma with the heading "Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe". Entry into Agreements with Advanz On May 22, 2023, Alvotech entered into a

24 May '23

Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe

Advanz Pharma secures exclusive rights from Alvotech to commercialize five proposed biosimilars in Europe The agreement includes proposed biosimilars to Simponi ® (golimumab), Entyvio ® (vedolizumab) and three additional early-stage undisclosed biosimilar candidates Advanz Pharma will leverage its

HTML íslensk útgáfa

19 May '23

Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update

Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period in 2022 Confirmatory patient study for AVT05, a proposed biosimilar for Simponi ® and Simponi Aria ® (golimumab) initiated, marking the fifth internally developed portfolio candidate

HTML íslensk útgáfa

17 May '23

Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit

REYKJAVIK, Iceland, May 17, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley Annual Sustainable Finance Summit on May 22,

HTML íslensk útgáfa

15 May '23

Alvotech Issues Annual Equality Report Covering 2022

Alvotech’s global workforce is now evenly split between females and males, and the unexplained gender pay gap has been reduced to 1.6% from 5.2% in December 2020 Alvotech’s Equality Policy, which is based on Icelandic law, has been implemented for the workforce globally REYKJAVIK, Iceland, May 15,

HTML íslensk útgáfa

10 May '23

Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)

Polifarma will commercialize AVT06, a proposed biosimilar to Eylea ® (aflibercept), in Turkey REYKJAVIK, Iceland, May 10, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today

HTML íslensk útgáfa

First page
Previous page
…
Page 13
Page 14
Page 15
Page 16
Current page 17
Page 18
Page 19
Page 20
Page 21
…
Next page
Last page

Displaying 161 - 170 of 275